loading
Neurocrine Biosciences Inc stock is traded at $118.73, with a volume of 1.23M. It is up +1.47% in the last 24 hours and up +24.98% over the past month. Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$116.87
Open:
$117.8
24h Volume:
1.23M
Relative Volume:
0.79
Market Cap:
$11.77B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
40.25
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
-2.48%
1M Performance:
+24.98%
6M Performance:
-3.49%
1Y Performance:
-14.36%
1-Day Range:
Value
$116.00
$121.85
1-Week Range:
Value
$115.66
$121.85
52-Week Range:
Value
$84.23
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Name
Neurocrine Biosciences Inc
Name
Phone
(858) 617-7600
Name
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Employee
1,800
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
NBIX's Discussions on Twitter

Compare NBIX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
118.72 11.77B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
155.02 66.72B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.42 48.08B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.69 47.74B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.70 18.49B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
298.88 13.31B 2.99B 1.21B 1.13B 25.06

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-25 Upgrade Needham Hold → Buy
Apr-14-25 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-11-25 Initiated Deutsche Bank Hold
Oct-10-24 Resumed Raymond James Outperform
Aug-29-24 Upgrade Piper Sandler Neutral → Overweight
Apr-24-24 Upgrade Wells Fargo Equal Weight → Overweight
Dec-13-23 Resumed Citigroup Neutral
Dec-12-23 Initiated Deutsche Bank Buy
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Aug-21-23 Reiterated Mizuho Neutral
Jul-24-23 Upgrade SVB Securities Market Perform → Outperform
Jul-06-23 Upgrade BMO Capital Markets Underperform → Market Perform
May-04-23 Upgrade Guggenheim Neutral → Buy
Mar-30-23 Upgrade Canaccord Genuity Hold → Buy
Mar-03-23 Upgrade Evercore ISI In-line → Outperform
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-14-22 Downgrade Evercore ISI Outperform → In-line
Oct-11-22 Initiated UBS Buy
Sep-26-22 Initiated Wells Fargo Equal Weight
Jun-06-22 Resumed Jefferies Buy
Mar-03-22 Downgrade Piper Sandler Overweight → Neutral
Feb-25-22 Upgrade Goldman Neutral → Buy
Jan-18-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-21 Initiated BMO Capital Markets Underperform
Nov-17-21 Upgrade JP Morgan Neutral → Overweight
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Aug-06-21 Downgrade Canaccord Genuity Buy → Hold
May-18-21 Resumed Goldman Neutral
May-06-21 Upgrade Barclays Equal Weight → Overweight
Feb-02-21 Initiated Raymond James Outperform
Sep-30-20 Initiated The Benchmark Company Hold
Aug-04-20 Downgrade JP Morgan Overweight → Neutral
Jun-29-20 Downgrade Goldman Buy → Neutral
Jun-09-20 Initiated Wedbush Outperform
Mar-06-20 Initiated Citigroup Buy
Feb-27-20 Initiated Barclays Equal Weight
Feb-24-20 Initiated William Blair Outperform
Feb-06-20 Initiated Mizuho Neutral
Feb-05-20 Reiterated H.C. Wainwright Buy
Dec-13-19 Downgrade Credit Suisse Outperform → Neutral
Aug-07-19 Initiated RBC Capital Mkts Outperform
Jul-16-19 Initiated Oppenheimer Outperform
Jun-05-19 Initiated Guggenheim Neutral
May-21-19 Initiated Credit Suisse Outperform
Apr-22-19 Upgrade JP Morgan Neutral → Overweight
Apr-12-19 Initiated Evercore ISI Outperform
Feb-06-19 Reiterated BofA/Merrill Buy
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Dec-13-18 Initiated Goldman Buy
Nov-21-18 Initiated Canaccord Genuity Buy
View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

pulisher
May 13, 2025

Neurocrine at BofA Conference: Strategic Moves and Market Challenges - Investing.com

May 13, 2025
pulisher
May 13, 2025

Learn to Evaluate (NBIX) using the Charts - news.stocktradersdaily.com

May 13, 2025
pulisher
May 13, 2025

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Neurocrine Biosciences To Present BofA Securities 2025 Health Care Conference; Webcast At 2:20 PM ET - Nasdaq

May 13, 2025
pulisher
May 12, 2025

Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 Analysis - HCPLive

May 12, 2025
pulisher
May 12, 2025

Cognitive Impairment Associated with Schizophrenia Pipeline - openPR.com

May 12, 2025
pulisher
May 12, 2025

Cognitive Impairment Associated with Schizophrenia Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Cyclerion Therapeutics, Biogen, Neurocrine - Barchart.com

May 12, 2025
pulisher
May 12, 2025

Investors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Quality - Yahoo Finance

May 12, 2025
pulisher
May 11, 2025

Earnings Tell The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) As Its Stock Soars 27% - simplywall.st

May 11, 2025
pulisher
May 10, 2025

Wedbush Lifts Earnings Estimates for Neurocrine Biosciences - Defense World

May 10, 2025
pulisher
May 09, 2025

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com

May 09, 2025
pulisher
May 09, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $160.00 - Defense World

May 09, 2025
pulisher
May 09, 2025

Wedbush Forecasts Lower Earnings for Neurocrine Biosciences - Defense World

May 09, 2025
pulisher
May 08, 2025

Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

May 08, 2025
pulisher
May 08, 2025

Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Neurocrine leans on singer Carnie Wilson for tardive dyskinesia push - Medical Marketing and Media

May 08, 2025
pulisher
May 08, 2025

Neurocrine Reports Late Stage Data Of Crenessity - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgrou - Longview News-Journal

May 08, 2025
pulisher
May 08, 2025

Neurocrine surges 13% on Q1 revenue beat, reaffirmed 2025 guidance - MSN

May 08, 2025
pulisher
May 07, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 07, 2025
pulisher
May 07, 2025

Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target - Investing.com Australia

May 07, 2025
pulisher
May 07, 2025

Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday - Insider Monkey

May 07, 2025
pulisher
May 07, 2025

Neurocrine Bio stock target raised at Needham following earnings By Investing.com - Investing.com South Africa

May 07, 2025
pulisher
May 07, 2025

Neurocrine Bio stock target raised at Needham following earnings - Investing.com Australia

May 07, 2025
pulisher
May 07, 2025

RBC Capital lifts Neurocrine Bio. stock target to $145 on sales momentum By Investing.com - Investing.com South Africa

May 07, 2025
pulisher
May 07, 2025

RBC Capital lifts Neurocrine Bio. stock target to $145 on sales momentum - Investing.com Nigeria

May 07, 2025
pulisher
May 07, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up Following Analyst Upgrade - Defense World

May 07, 2025
pulisher
May 07, 2025

Neurocrine Biosciences (NBIX) Receives Price Target Raise from C - GuruFocus

May 07, 2025
pulisher
May 06, 2025

Neurocrine Biosciences’ Earnings Call Highlights Growth Amid Challenges - TipRanks

May 06, 2025
pulisher
May 06, 2025

Traders Purchase Large Volume of Put Options on Neurocrine Biosciences (NASDAQ:NBIX) - Defense World

May 06, 2025
pulisher
May 06, 2025

NBIX: Analyst BMO Capital Raises Price Target for Neurocrine Bio - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May - Longview News-Journal

May 06, 2025
pulisher
May 06, 2025

Guggenheim Ups Price Target for Neurocrine (NBIX) Amid Ingrezza Sales Performance | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences (NBIX) Price Target Raised by RBC Capital | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences Stock Price, Quotes and Forecasts | NASDAQ:NBIX - Benzinga

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target - Benzinga

May 06, 2025
pulisher
May 06, 2025

Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target By Investing.com - Investing.com India

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug - inkl

May 06, 2025
pulisher
May 06, 2025

2 Pharma Stocks Staging Big Post-Earnings Moves - Schaeffer's Investment Research

May 06, 2025
pulisher
May 06, 2025

NBIX: Analyst BMO Capital Raises Price Target for Neurocrine Biosciences | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences (NBIX) Target Price Raised by UBS Analyst | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Wedbush Boosts Neurocrine (NBIX) Price Target Following Strong R - GuruFocus

May 06, 2025
pulisher
May 06, 2025

BofA Securities Adjusts Price Target on Neurocrine Biosciences to $183 From $179, Maintains Buy Rating - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Wedbush Boosts Neurocrine (NBIX) Price Target Following Strong Results | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences and Carnie Wilson Team Up to Launch Conne - GuruFocus

May 06, 2025
pulisher
May 06, 2025

RBC Capital Increases Price Target for Neurocrine (NBIX) to $145 | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - Longview News-Journal

May 06, 2025
pulisher
May 06, 2025

UBS Elevates Neurocrine (NBIX) Price Target and Highlights Growth Prospects | NBIX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Neurocrine (NBIX) Sees Price Target Adjustment Amid Strong Earni - GuruFocus

May 06, 2025
pulisher
May 06, 2025

RBC Raises Price Target on Neurocrine Biosciences to $145 From $137, Keeps Outperform Rating - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Neurocrine Biosciences (NBIX) Receives Price Target Raise from Canaccord Genuity | NBIX Stock News - GuruFocus

May 06, 2025

Neurocrine Biosciences Inc Stock (NBIX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$14.15
price up icon 0.39%
$299.55
price down icon 2.74%
$8.455
price down icon 3.81%
$79.53
price up icon 0.73%
$16.68
price down icon 4.49%
Cap:     |  Volume (24h):